Fresh From the Bench: Latest Federal Circuit Court Cases
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASE OF THE WEEK
ESIP Series 2, LLC v. Puzhen Life USA, LLC, Appeal No. 2019-1659 (Fed. Cir. May 19, 2020)
In this week’s Case of the Week, the Federal Circuit affirmed an inter partes review decision finding challenged claims obvious, extending recent Supreme Court precedent immunizing many IPR institution decisions from appellate review.
On appeal, the appellant patent owner argued that the Patent Trial and Appeal Board should not have instituted inter partes review because the petitioner failed to identify all real parties-in-interest as required by 35 U.S.C. § 312(a)(2). The Federal Circuit held that because the Board’s decision raised an ordinary dispute about the application of an institution-related statute, appellate review was barred by § 314(d). In so holding, the Court applied and extended the Supreme Court’s decisions in Cuozzo Speed Techs. v. Lee, 136 S. Ct. 2131 (2016) (§ 314(d) precluded judicial review of Board decisions concerning the “particularity” requirement of § 312(a)(3)) and Thryv, Inc. v. Click-To-Call Techs., LP, 140 S. Ct. 1367 (2020) (§ 314(d) precluded review of decisions concerning the one-year time bar of § 315(b)). In light of this precedent, the Federal Circuit explained that it could find no principled reason why preclusion of judicial review should not extend to real party-in-interest determinations under § 312(a)(2).
Read More.
ALSO THIS WEEK
Odyssey Logistics and Technology Corp. v. Andrei Iancu, Appeal No. 2019-1066 (Fed. Cir. May 22, 2020)
This appeal concerns a lawsuit filed in the Eastern District of Virginia to challenge three issues: procedural rules promulgated by the PTO concerning ex parte appeals, and also actions taken by the PTO during the prosecution of two patents. The district court found that it did not have subject matter jurisdiction over the issues concerning the prosecution of the two patents, because those prosecutions were not “final”; issues in those prosecutions remained pending. With respect to the attack on the PTO’s procedural rules, the district court held that the statute of limitations had expired, because the legal challenge was made more than six years after the regulations were published, even though they were within six years of the effective date. Thus, the district court dismissed the action. The Federal Circuit affirmed, adopting the same positions as the district court.
The opinion can be found here.
McRO, Inc. v. Bandai Namco Games Am. Inc., Appeal No. 2019-1557 (Fed. Cir. May 20, 2020).
In this appeal from the U.S. District Court for the Central District of California, the Federal Circuit overturned the district court’s ruling that a patent claiming a method for automatically generating 3-D animations depicting certain facial movements and expressions is not enabled under 35 USC § 112. The Court found that the district court’s reasoning was too abstract and conclusory to support summary judgment of non-enablement because the two potentially infringing processes at issue—which the Court ultimately found non-infringing—were not available as claim-covered techniques. A non-enablement determination could not be supported, the Court held, because defendants and the district court failed to identify with particularity any method of animation that falls within the scope of the asserted claims.
The opinion can be found here.
Written by: Scott D. Eads and Nika Aldrich, Schwabe Williamson & Wyatt
Contributors: Jason Wrubleski and Erin Forbes
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…